Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
about
New advances in targeted gastric cancer treatmentImmunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersTargeted therapy for advanced gastric cancer: A review of current status and future prospectsSite-specific functionalization of proteins and their applications to therapeutic antibodiesCurrent role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinomaEvaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal CancerMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerIgE immunotherapy against cancerIgE-based immunotherapy of cancer: challenges and chances.Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).S100P: a novel therapeutic target for cancer.Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysBi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumorsNovel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Masked Chimeric Antigen Receptor for Tumor-Specific Activation.Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesModular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.Molecular targeting to treat gastric cancer.Understanding the economic value of molecular diagnostic tests: case studies and lessons learned.Current status of novel agents in advanced gastroesophageal adenocarcinoma.Genetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection.Plakophilin-2 induced EGFR phosphorylation: a focus on the intracellular activators of EGFRTherapeutic antibodies against cancer.High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor ReceptorPharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')(2) Fragment in an Immunocompetent Mouse ModelMolecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathwaysNADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicitySym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximabPanitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Cetuximab (erbitux).Towards novel paradigms for cancer therapy.Personalized medicine - the promised land: are we there yet?Molecular targeted agents for gastric and gastroesophageal junction cancer.Immunocombination therapy for high-risk neuroblastoma.
P2860
Q26738548-11A6510B-1CF8-4B3F-99FD-942293F71FC9Q26751473-6F5D7250-A1E4-46BD-8F1A-E4BB0FA021D4Q26774138-717B4EA2-F7AE-430B-99B2-7F97CA3A8367Q26830699-CC09E856-86A9-4FBE-83A2-37225FF74C0CQ26991953-0EBE6AE9-901B-4706-99A6-948516547B6DQ28074285-7C9FCF39-FD54-4854-8091-977FEC7428BAQ28076490-F497901F-9A72-4A0C-9CBD-41D5DA9FAB50Q28081223-98305955-9E24-4F27-BB1B-9BC841827AC5Q33619979-295D649B-7854-4524-9D50-7BAADF8D34D2Q33658636-266D9B72-6C66-4161-9EDC-EE8FC782F392Q33699305-B9A9A3A7-AB8E-436F-A66C-B98B28F890ADQ33700990-5F43E7D6-D64F-4E8F-8F60-AB121243C6C5Q33737298-276EF72F-420F-4742-B091-9D1D268CA1A7Q33753135-9B3CE29A-4C90-45A5-B1B2-D33FC3EB784DQ33888876-F411604D-1143-4EB3-A920-EAD4287D924EQ33903025-B0ABE24D-3779-4E9C-A195-4A2D6301D726Q34047878-B263F397-C999-4872-AAD6-35865840B778Q34067821-D87DCAB8-6BDD-410B-AAB7-C0CB797C75E8Q34088424-C0DDDD38-9A58-46FE-9E33-4D1FE4BAC5A8Q34162031-DDF659AC-D04F-4949-8CD6-1215464CDE99Q34326593-6944E734-89FB-46A7-903A-8461F95E9FA4Q34608705-F6ACCFAC-D606-441F-89D4-075CDC2C28EEQ34962039-BB750C3F-411E-4A66-944D-65A0F214F957Q35022791-04816192-4FA6-40DF-9A2D-D22010B03E0CQ35618896-4B948444-5B8B-4975-8208-54F837C9008DQ35908498-F8A6C153-275C-4A8B-B54A-206E2D096CEDQ36089600-28A61A90-AE77-4579-811A-668907531D58Q36335893-E7640096-9C56-4B0E-BFEF-E378B40AE0F6Q36339837-426B14D3-7947-4169-AA27-1C5266C20B03Q36388482-76B8CBFE-3694-4279-89E6-C4D231652045Q36440219-E010625F-07EB-44C9-8E3C-FC413F139556Q36545995-7DDC9DB7-4D9D-4F24-B467-DB21B95D9129Q36656128-65AC86A8-60EA-40B3-B9EA-BB0B7EB521D9Q37285565-391DB214-150E-47FD-B509-51601F67CFBEQ37615896-E20AB398-8770-4058-BD16-427C43947B0CQ37694893-45C47D2C-FCC2-4DEF-8870-2A27121046B6Q37799251-3F9776D3-E1C5-4E32-86AD-536270FE09B0Q37825915-2AFE2279-D022-4AF0-A36E-0A799FAB6C25Q37962816-D1BE67C3-9609-401B-B276-D251CAD08747Q37991024-69C55B63-C837-4DBC-9CED-AE3C0D983262
P2860
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@en
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@nl
type
label
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@en
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@nl
prefLabel
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@en
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
@nl
P2860
P50
P921
P1476
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
@en
P2093
E Martinelli
P2860
P356
10.1111/J.1365-2249.2009.03992.X
P577
2009-10-01T00:00:00Z